Comparing tele-pharmacy and standard clinic follow-up for newly initiated warfarin anticoagulation therapy

References

1. 1.↵
   1. Ritchie LA,
   2. Penson PE,
   3. Lane DA.

   Warfarin-is self-care the best care? ThrombHaemost. 2022; 122: 471–474.

   OpenUrlPubMed
2. 2.↵
   1. Olie RH,
   2. Winckers K,
   3. Rocca B,
   4. Ten Cate H.

   Oral anticoagulants beyond warfarin. Annu Rev Pharmacol Toxicol 2024: 64: 551-575.

   OpenUrlPubMed
3. 3.↵
   1. Rosendaal FR,
   2. Cannegieter SC,
   3. Van Der Meer FJM,
   4. Briet E.

   Thrombosis and Haeniostasis-A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.

   OpenUrlPubMedWeb of Science
4. 4.↵
   1. Witt DM,
   2. Nieuwlaat R,
   3. Clark NP,
   4. Ansell J,
   5. Holbrook A,
   6. Skov J, et al.

   American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2: 3257–3291.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Turen S,
   2. Turen S.

   Determination of Factors Affecting Time in Therapeutic Range in Patients on Warfarin Therapy. Biol Res Nurs 2023; 25: 170-178.

   OpenUrlPubMed
6. 6.↵
   1. Tadesse TA,
   2. Gebremedhin A,
   3. Yadeta D,
   4. Chelkeba L,
   5. Fenta TG.

   Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study. Journal of Pharmaceutical Health Care and Sciences. J Pharm Health Care Sci 2024; 10: 32.

   OpenUrlPubMed
7. 7.
   1. Alghadeeer S,
   2. Alzahrani AA,
   3. Alalayet WY,
   4. Alkharashi AA,
   5. Alarifi MN.

   Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: A prospective observational study. Risk Manag Healthc Policy 2020; 13: 1175-1179.

   OpenUrlPubMed
8. 8.↵
   1. Noor A,
   2. Khan MA,
   3. Warsi A,
   4. Aseeri M,
   5. Ismail S.

   Evaluation of a pharmacist vs. Haematologist-managed anticoagulation clinic: A retrospective cohort study. Saudi Pharm J 2021; 29: 1173–1180.

   OpenUrlPubMed
9. 9.↵
   1. Barrios V,
   2. Cinza-Sanjurjo S,
   3. García-Alegría J,
   4. Freixa-Pamias R,
   5. Llordachs-Marques F,
   6. Molina CA, et al.

   Role of Telemedicine in the Management of Oral Anticoagulation in Atrial Fibrillation: A Practical Clinical Approach. Future Cardiol 2022; 18743-754.
10. 10.↵
    1. Bussey HI,
    2. Nutescu EA,
    3. Harper P.

    Can clinical pharmacists utilize telehealth to double the safety and efficacy of oral anticoagulation while reducing health care costs and improving patient satisfaction in patients with atrial fibrillation? JACCP 2021; 4: 969-977.

    OpenUrl
11. 11.↵
    1. Dhippayom T,
    2. Rattanachaisit N,
    3. Jhunsom S,
    4. Dilokthornsakul P,
    5. Chaiyakunapruk N,
    6. Devine B.

    Comparative effects of telemedicine and face-to-face warfarin management: A systematic review and network meta-analysis. J Am Pharm Assoc (2003) 2020; 60: 880-891.e9.

    OpenUrl
12. 12.↵
    1. Sakunrag I,
    2. Danwilai K,
    3. Dilokthornsakul P,
    4. Chaiyakunapruk N,
    5. Dhippayom T.

    Clinical outcomes of telephone service for patients on warfarin: A systematic review and meta-analysis. Telemed J E Health 2020; 26: 1507–1521.

    OpenUrlPubMed
13. 13.↵
    1. Tran RJC,
    2. Yamzon J,
    3. Stewart TL,
    4. Hernandez EA,
    5. Cao DX.

    Effectiveness of Telepharmacy Versus Face-to-Face Anticoagulation Services in the Ambulatory Care Setting: A Systematic Review and Meta-analysis. Ann Pharmacother 2021; 55: 1084–1095.

    OpenUrlPubMed
14. 14.↵
    1. Braga Ferreira L,
    2. Lanna de Almeida R,
    3. Arantes A,
    4. Abdulazeem H,
    5. Weerasekara I,
    6. Ferreira LSDN, et al.

    Telemedicine-based management of oral anticoagulation therapy: systematic review and meta-analysis. J Med Internet Res 2023; 25: e45922.

    OpenUrlPubMed
15. 15.↵
    1. Alanazi Z,
    2. Almutairi N,
    3. AlDukkan L,
    4. Arafat AA,
    5. Albabtain MA.

    Time in therapeutic range for virtual anticoagulation clinic versus in-person clinic during the COVID-19 pandemic: a crossover study. Ann Saudi Med 2022; 42: 305–308.

    OpenUrlPubMed
16. 16.↵
    1. Al Ammari M,
    2. AlThiab K,
    3. AlJohani M,
    4. Sultana K,
    5. Maklhafi N,
    6. AlOnazi H, et al.

    Tele-pharmacy anticoagulation clinic during covid-19 pandemic: patient outcomes. Front Pharmacol 2021; 12.
17. 17.↵
    1. von Elm E,
    2. Altman DG,
    3. Egger M,
    4. Pocock SJ,
    5. Gøtzsche PC,
    6. Vandenbroucke JP.

    The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. J Clin Epidemiol 2014; 12: 1495–1499.

    OpenUrl
18. 18.↵
    1. Hartenstein A,
    2. Abdelgawwad K,
    3. Kleinjung F,
    4. Privitera S,
    5. Viethen T,
    6. Vaitsiakhovich T.

    Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources. Int J Popul Data Sci 2023; 8: 2144.

    OpenUrlPubMed
19. 19.↵
    1. Alshihab S,
    2. Mohamed Ibrahim MI,
    3. Hadi MA,
    4. Syed A,
    5. Arabi A,
    6. Al-Qahtani A, et al.

    Evaluation of warfarin management in primary health care centers in Qatar: A retrospective cross-sectional analysis of the national dataset. Curr Probl Cardiol 2024; 49: 102427.

    OpenUrlPubMed
20. 20.↵
    1. Gateman D,
    2. Trojnar ME,
    3. Agarwal G.

    Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice. Can Fam Physician 2017; 63: e425–e431.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Albabtain MA,
    2. Alharthi MM,
    3. Dagriri K,
    4. Arafat AA,
    5. Ayrout E,
    6. Alhebaishi Y, et al.

    Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J 2020; 41: 1245–1251.

    OpenUrlAbstract/FREE Full Text
22. 22.
    1. Farsad BF.

    Evaluation of Time in Therapeutic Range (TTR) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran, Iran: A cross-sectional study. J Clin Diagn Res 2016; 10: FC04-FC06.

    OpenUrl
23. 23.
    1. Hakeem H,
    2. Khan AZ,
    3. Aziz K,
    4. Abbasi A,
    5. Haider A,
    6. Moiz B, et al.

    Evaluation of quality of warfarin therapy by assessing patient’s time in therapeutic range at a tertiary care hospital in Pakistan. J Pak Med Assoc 2018; 68: 1339–1344.

    OpenUrlPubMed
24. 24.↵
    1. Kılıç S,
    2. Çelik A,
    3. Çakmak HA,
    4. Afşin A,
    5. Tekkeşin Aİ,
    6. Açıksarı G, et al.

    The time in therapeutic range and bleeding complications of warfarin in different geographic regions of Turkey: A subgroup analysis of WARFARIN-TR Study. Balkan Med J 2017; 34: 349-355.

    OpenUrlPubMed